Selank is a synthetic peptide widely studied in neuropharmacology research for its interaction with anxiety-related and cognitive signalling pathways. This article provides an educational overview of what the published scientific literature reports about Selank, its structure, and its mechanisms of interest. All information below is provided strictly for research and informational purposes.
What is Selank?
Selank is a synthetic heptapeptide (a chain of seven amino acids, sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed from the naturally occurring peptide tuftsin. It was originally developed by researchers at the Russian Academy of Sciences. Research literature notes that Selank exhibits greater stability than its natural counterpart. It is typically supplied as a lyophilised powder for research use.
Mechanisms of interest
Scientific interest in Selank centres on its reported activity across several neurological pathways in research models. The published literature describes its study in relation to:
- GABAergic modulation — research describes Selank as acting as a positive allosteric modulator of GABA receptors, through a mechanism reported to differ from classical benzodiazepines.
- Neurotransmitter systems — studies have examined its influence on serotonergic, dopaminergic and noradrenergic signalling.
- Enkephalin regulation — research has investigated its effect on enzymes that break down enkephalins, which may influence its reported activity.
- BDNF and neuroplasticity — some studies have explored its association with brain-derived neurotrophic factor and synaptic plasticity in research models.
What the research has reported
Selank has been the subject of both preclinical and some clinical research, with a notable body of work examining anxiolytic and nootropic activity in study settings — including clinical research in generalised anxiety contexts. Researchers note that much of the evidence base originates from Russian research institutions, with comparatively limited international validation and long-term data, meaning broader study is still developing.
Regulatory status in Australia
Selank has not been approved by the Therapeutic Goods Administration (TGA), is not listed on the Australian Register of Therapeutic Goods (ARTG), and is not approved for therapeutic use. It is supplied strictly as a research compound.
Important disclaimer
This article is provided for informational and laboratory-research purposes only. Selank is supplied strictly as a research compound, for in-vitro laboratory research use only. It is not for human or animal consumption. Nothing in this article constitutes medical advice, nor a recommendation for use in humans. Always refer to current published literature and applicable regulations.